Other languages Scandion Oncology A/S

Equities

SCOL

DK0061031895

Delayed Nasdaq Stockholm Other stock markets 03:55:07 2024-06-27 EDT			5-day change	1st Jan Change
0.288 ^SEK	-0.69%		-26.53%	-92.79%

05-22	Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024
05-22	Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-22
Scandion Confirms Positive Final Phase Ib Data from Pantax Trial with Sco-101	05-13
Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival	03-21
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial	03-07
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-28
Scandion Oncology A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28
Scandion Oncology Reports Positive Topline Phase IIa Data from the CORIST Part 3 Trial	01-31
Scandion Oncology Receives Notice of Allowance for Patent to Enhance US Patent Exclusivity on SCO-101	01-05
Scandion Oncology Announces Presenting Topline Data in the Ongoing Corist Part 3 Study	12-21
Scandion Oncology Completes Pre-Clinical Studies and Identifies Potentially Effective Treatment of Gastric Cancer	12-15
Scandion Oncology Obtains Patent for Combination Cancer Treatment Drug	11-29
Scandion Oncology A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-22
Scandion Oncology Announces Positive Data from Part 2 of its International Multi-Center CORIST Open Label Phase IIa Trial	11-21
Scandion Oncology Successfully Completes Phase Ib Pantax Trial Is and Establishes the Maximal Tolerated Dose with Positive Safety Profile and Pharmacokinetic Data	23-10-15
Scandion Oncology A/S Appoints Lars Damstrup, MD, PhD, as Chief Medical Officer	23-09-12
Scandion Oncology A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23
Scandion Oncology A/S Announces Data from PANTAX Trial to Be Presented At ESMO Congress 2023	23-08-17
The European Patent Office Announces Intention to Grant of Composition-Of-Matter Patent for Scandion Oncology's Lead Compound SCO-101	23-07-18
Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-26
Scandion Oncology A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Scandion Oncology A/S

Equities

SCOL

DK0061031895

Other languages

Filters